138 related articles for article (PubMed ID: 16481646)
1. Autoimmunity and immunotherapy for cancer.
Koon H; Atkins M
N Engl J Med; 2006 Feb; 354(7):758-60. PubMed ID: 16481646
[No Abstract] [Full Text] [Related]
2. Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Gogas H; Ioannovich J; Dafni U; Stavropoulou-Giokas C; Frangia K; Tsoutsos D; Panagiotou P; Polyzos A; Papadopoulos O; Stratigos A; Markopoulos C; Bafaloukos D; Pectasides D; Fountzilas G; Kirkwood JM
N Engl J Med; 2006 Feb; 354(7):709-18. PubMed ID: 16481638
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
[TBL] [Abstract][Full Text] [Related]
4. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
[TBL] [Abstract][Full Text] [Related]
5. [After removal of a malignant melanoma. Enhancing the immune system!].
MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
[No Abstract] [Full Text] [Related]
6. Autoimmunity aids survival in melanoma.
Senior K
Lancet Oncol; 2006 Apr; 7(4):289. PubMed ID: 16598882
[No Abstract] [Full Text] [Related]
7. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.
Tarhini AA; Shin D; Lee SJ; Stuckert J; Sander CA; Kirkwood JM
Melanoma Res; 2014 Apr; 24(2):150-7. PubMed ID: 24509407
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta E
Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
[No Abstract] [Full Text] [Related]
9. Adjuvant therapy for melanoma: a surgical perspective.
Sondak VK; Gonzalez RJ; Kudchadkar R
Surg Oncol Clin N Am; 2011 Jan; 20(1):105-14. PubMed ID: 21111961
[TBL] [Abstract][Full Text] [Related]
10. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.
Killock D
Nat Rev Clin Oncol; 2015 Aug; 12(8):438. PubMed ID: 26077044
[No Abstract] [Full Text] [Related]
11. Interferon as adjuvant treatment for melanoma.
Wheatley K; Ives N; Hancock B; Gore M
Lancet; 2002 Sep; 360(9336):878. PubMed ID: 12243953
[No Abstract] [Full Text] [Related]
12. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
13. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
Hauschild A; Gogas H; Tarhini A; Middleton MR; Testori A; Dréno B; Kirkwood JM
Cancer; 2008 Mar; 112(5):982-94. PubMed ID: 18236459
[TBL] [Abstract][Full Text] [Related]
14. New applications of cancer immunotherapy.
Agarwala SS
Semin Oncol; 2002 Jun; 29(3 Suppl 7):1-4. PubMed ID: 12068381
[No Abstract] [Full Text] [Related]
15. The role of adjuvant interferon in high risk melanoma patients.
Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
[No Abstract] [Full Text] [Related]
16. Prediction of response to anticancer immunotherapy using gene signatures.
Wang E; Bedognetti D; Marincola FM
J Clin Oncol; 2013 Jul; 31(19):2369-71. PubMed ID: 23715576
[No Abstract] [Full Text] [Related]
17. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
19. [Feasability and tolerance of adjuvant treatment of melanoma with immunotherapy according to Kirkwood protocol].
Uwer L; Martin S; Geoffrois L; Schmutz JL
Ann Dermatol Venereol; 2005 Jan; 132(1):50-1. PubMed ID: 15746611
[No Abstract] [Full Text] [Related]
20. Malignant melanoma: non-metastatic.
Crosby D; Crosby T; Mason M
Clin Evid; 2002 Jun; (7):1519-29. PubMed ID: 12230768
[No Abstract] [Full Text] [Related]
[Next] [New Search]
